BioPharma DiveOriginal article
Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
Phase 3positiveVaxcyte pneumococcal vaccinePositive
AI Analysis
Summary
Vaxcyte's next-generation pneumococcal vaccine demonstrated positive Phase 3 data, matching the effectiveness of Pfizer and Merck vaccines on nearly all bacterial strains in the first of three pivotal trials, exceeding Wall Street expectations.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Vaccine matched effectiveness of Pfizer and Merck vaccines on nearly all bacterial strains in first of three Phase 3 trials
Importance:7/10
Sentiment:
0.85
vaccinepneumococcalPhase 3clinical trialpositive data
Read the original article
Published by BioPharma Dive on October 5, 2026 1:52 PM